BIIB vs EXEL
Biogen Inc. (BIIB) and Exelixis, Inc. (EXEL) are both filed with the SEC under Biological Products, (No Diagnostic Substances). BIIB is 2.4× EXEL's size by market cap ($32.7B against $13.7B); EXEL trades at the higher fiscal-year P/E (31.4× against 25.2×); EXEL reports the higher net margin (33.7% against 13.1%); EXEL grew sales faster over three years (+12.9% against -0.9%); and over the past year BIIB returned +64.7% against EXEL's +43.7%.
| BIIB | EXEL | |
|---|---|---|
| Last close | $218.50 | $54.45 |
| Market cap | $32.7B | $13.7B |
| P/E (FY) | 25.2× | 31.4× |
| P/S | 3.3× | 5.9× |
| Operating margin | 28.7% | 37.6% |
| Net margin | 13.1% | 33.7% |
| Return on equity | — | 35.5% |
| Sales growth (3y) | -0.9% | +12.9% |
| EPS growth (3y) | -25.0% | +70.6% |
| 1-year return | +64.7% | +43.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: BIIB FY2025 (ended 2025-12-31); EXEL FY2026 (ended 2026-01-02). — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| BIIB | EXEL | |
|---|---|---|
| Institutional holders (13F) | 997 | 693 |
| Insider buyers − sellers (180d) | — | -5 |
| Congressional trades disclosed (180d) | 6 | 0 |
| Executive-branch officials on file — trades disclosed (180d) | 3 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5. — no open-market Form 4 purchases or sales in the window.
BIIB vs EXEL: common questions
- Is BIIB bigger than EXEL?
- BIIB carries the larger market cap — $32.7B against $13.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, BIIB or EXEL?
- EXEL, at a fiscal-year 31.4× against 25.2× for BIIB. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have BIIB and EXEL performed over the past year?
- BIIB returned +64.7% and EXEL +43.7%, measured on the trailing calendar year to the last close.
- How many institutions hold BIIB and EXEL?
- 997 13F filers report a position in BIIB and 693 in EXEL, on the latest quarter in the panel.
- Are BIIB and EXEL in the same industry?
- Both are filed with the SEC under Biological Products, (No Diagnostic Substances), which is the classification this pairing is built on.
BIIB overview → · EXEL overview → · BIIB institutional ownership → · EXEL institutional ownership → · Congress and BIIB → · Executive branch and BIIB →
More in Biological Products, (No Diagnostic Substances): AMGN vs BIIB · AMGN vs EXEL · AMGN vs GILD · AMGN vs HALO
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/biib-vs-exel